Search
Minimally Invasive and Robotic Thoracic Surgery
UCSF Health offers a robotic thoracic surgery program specializing in treating thoracic disease.Brachytherapy Improves Outcomes for Cervical Cancer Patients
Patients with locally advanced cervical cancer who receive chemoradiation therapy and brachytherapy and complete treatment within eight weeks have a superior overall survival rate compared to those who don’t receive this treatment, according to a UCSF study.First-line Pembrolizumab Plus Chemotherapy May Benefit Patients with Advanced Biliary Tract Cancers
The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the phase III KEYNOTE-966 clinical trial.Radioligand Therapy Plus Pembrolizumab May Benefit Patients with Advanced Prostate Cancer
Immune checkpoint inhibitors have demonstrated limited efficacy in treating prostate cancer. Efforts to improve outcomes with combination therapies have mostly failed to demonstrate improvements compared to other types of cancer.Research Reveals Mechanisms at Work in Progression of Pancreatic Cysts to Pancreatic Cancer
Tumor Immune Microenvironments May Provide Clues to Future TherapiesUCSF Health Cancer Services Earns National Accreditation from the Commission on Cancer of the American College of Surgeons
The UCSF cancer program has been continuously accredited by the CoC since 1933, demonstrating its commitment to the best outcomes possible for its cancer patients.Personalized Therapy for Early-Stage Lung Cancer at UCSF
Follow the journey of a UCSF patient with early-stage, high-risk lung cancer, from history to treatment and prognosis, including how surgeons chose to do a robotic assisted VATS lobectomy and an analysis of how well chemo is likely to work for her.Updates from the American Society of Clinical Oncology (ASCO) 2017
A June 2017 Bay Area Breast Cancer Forum discussion of updates from the ASCO annual meeting, covering PARP inhibitors, germline BRCA mutations, HER2-positive cancer, patient-reported outcomes, immunotherapy and more. Moderator: Dr. Hope RugoInternational Hematologic Conference Features UCSF Health Experts
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 64th Annual Meeting and Exposition.Advances in Treating Colorectal Cancer With Liver Metastases
Giving new hope to potentially thousands of patients, surgeons at UC San Francisco are now providing lifesaving procedures for many colorectal cancer patients whose cancer has spread to the liver.Cancer Immunotherapy Toxicity Evaluation (CITE) Program
UCSF Health’s new Cancer Immunotherapy Toxicity Evaluation (CITE) Program is a valuable resource for both patient care and provider consults.Killing Pancreatic Cancer with T Cells that Turbocharge Themselves
Novel Immunotherapy Pumps Out Cancer-Killing Cytokines Only Inside the TumorUCSF Health’s Eric Small, MD, Elected ASCO President for 2025-2026 Term
The American Society of Clinical Oncology (ASCO) has elected Eric J. Small, MD, FASCO, to serve as its president for the term beginning in June 2025.Drug Turns Cancer Gene Into "Eat Me" Flag for Immune System
UCSF-led study shows promising pre-clinical results in killing cancer cells resistant to current KRAS-targeted treatments.Rethinking How Cancer Cells Evade Targeted Therapy
Glioblastomas (GBMs) are incurable brain tumors with a prognosis of about one-and-a half years on average. They are highly resistant to treatment and have defied all attempts at precision therapy.UCSF Researchers Uncover New Pathway for Molecular Cancer Drug Therapies
In a study published December 8, 2022 in Science, UCSF researchers Kevin Lou, an MD-PhD student, Luke Gilbert, PhD, and Kevan Shokat, PhD, reveal the discovery of a cellular uptake pathway important for larger molecules.“CAR Pooling” Screens Identify Most Effective Cancer Immunotherapy Cells
New approach by UCSF researchers analyzes how well different re-engineered T cells work against cancer.UCSF500 Cancer Gene Panel Test
The UCSF500 Cancer Gene Panel leverages world-class expertise for advanced cancer cases. Designed by our leading cancer specialists, the UCSF500 offers unparalleled depth and precision in genetic analysis.New Keys to Cancer Care: How 2023 Findings Impact Treatment Decisions
These four collaborative talks from UCSF and John Muir Health specialists shine a light on recent study results that should inform treatment planning for patients with a variety of GI, breast, lung and blood cancers.Breast MRI and Advanced Breast Intervention
Bonnie Joe, MD, PhD, discusses how breast MRI is performed, common indications for breast MRI and advanced methods for biopsy and pre-surgical localization of tumors.Mammography 101
Bonnie Joe, MD explains the differences between screening and diagnostic mammography, shows evidence for screening, answers common questions about radiation risk and false positives and discusses digital breast tomosynthesis, also known as 3D mammography.Screening and Removal of Precancerous Lesions Prevents Anal Cancer
National study led by UCSF is first to show effectiveness of simple strategies to reduce risk of often silent cancer.Bladder Cancer Home Test Reduced Need for Cystoscopy During COVID-19
A study led by UCSF urologic cancer surgeons Sima Porten, MD, MPH, and Maxwell Meng, MD, found that use of a home urine test during the COVID-19 pandemic decreased the frequency of surveillance cystoscopy for patients with a history of non-muscle invasive bladder cancer (NMIBC).UCSF-Led Study Confirms Some Cancer Immunotherapies May Lead to Myocarditis and Other Potentially Serious Arrhythmias
Immune checkpoint inhibitors (ICIs) have transformed cancer care by unleashing T-cells to fight tumors, but they can cause serious cardiotoxicities including myocarditis.